Physician profile
David E Rivadeneira
NPI 1457370785
$271,310.94
in general payments reported to CMS, 2019-2025
41 companies · $64K in 2025
The $64K reported for 2025 was more than what 99% of Colon & Rectal Surgery providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $22K · 2021: $16K · 2022: $4,381 · 2023: $49K · 2024: $103K · 2025: $64K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $158K · Acquisitions: $39K · Travel and Lodging: $9,156 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,000 · Food and Beverage: $3,771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $158,000.00 |
| Acquisitions | $39,474.60 |
| Travel and Lodging | $9,156.36 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,000.00 |
| Food and Beverage | $3,771.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evologics LLC | $85,000.00 | 2024-2025 | |
| Dilon Technologies, INC. | $48,366.64 | 2022-2025 | Hemoblast Bellows |
| Stryker Corporation | $39,515.59 | 2023-2025 | Spy-Phi System |
| Biom'Up France Sas | $32,279.00 | 2020-2021 | |
| Integra Lifesciences Corporation | $26,328.26 | 2019-2024 | Integra, Omnigraft, Integra Dermal Regeneration Template |
| Guard Medical INC. | $17,055.30 | 2022-2025 | Npseal Large, Npseal (5), Npseal Medium |
| Applied Medical Resources Corporation | $11,059.22 | 2022-2024 | Gelport Laparoscopic System |
| Biom'Up Sa | $6,695.22 | 2019 | |
| Tei Biosciences INC | $3,091.38 | 2019 | |
| Intuitive Surgical, INC. | $243.77 | 2024 | |
| Boston Scientific Corporation | $208.39 | 2024-2025 | General - Hemostasis |
| Kci USA, INC. | $124.13 | 2019-2022 | |
| Davol INC. | $116.06 | 2021-2025 | Phasix Mesh |
| Heron Therapeutics, INC. | $112.37 | 2019-2024 | Zynrelef |
| Smith+Nephew, INC. | $111.78 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rivadeneira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.